B. McLaurin

发表

Patients With Diabetes at High Bleeding Risk With 1-Month Dual Antiplatelet Therapy: Onyx ONE Clear Results

M. Price, G. Stone, A. Kirtane, 2022, Journal of the Society for Cardiovascular Angiography & Interventions.

Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease

S. Saito, A. Baumbach, J. Wykrzykowska, 2021 .

Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.

José Miguel Contreras, G. Lip, J. De Sutter, 2021, The lancet. Diabetes & endocrinology.

Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus

S. Saito, A. Baumbach, M. Leon, 2022, Journal of the Society for Cardiovascular Angiography & Interventions.

Comparison of catheterization laboratory initiated abciximab and eptifibatide during percutaneous coronary intervention in acute coronary syndromes (an ACUITY substudy).

J. Ware, S. Pocock, H. White, 2010, The American journal of cardiology.

Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy

S. Saito, A. Baumbach, M. Leon, 2022, Journal of the Society for Cardiovascular Angiography & Interventions.

Outcomes of patients with coronary artery perforation complicating percutaneous coronary intervention and correlations with the type of adjunctive antithrombotic therapy: pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials.

G. Stone, A. Lincoff, R. Mehran, 2009, Journal of interventional cardiology.

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

R. D. Jenkins, Andreas Wilke, A. Capucci, 2022, Clinical Research in Cardiology.

Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents

Sunil V. Rao, M. Price, S. Pocock, 2020, Circulation. Cardiovascular interventions.

Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

S. Pocock, H. White, E. Ohman, 2008, Journal of the American College of Cardiology.

Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.

J. Ware, S. Pocock, H. White, 2007, JAMA.

Anticoagulant Selection in Relation to SAMe-TT2R2 Score in Patients with Atrial Fibrillation: The GLORIA-AF Registry.

R. D. Jenkins, A. Capucci, G. Lip, 2020, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease

S. Saito, A. Baumbach, J. Wykrzykowska, 2021, Circulation.

Normokinesia adjacent to left ventricular aneurysm: a differential risk for sudden cardiac death

D. Giurgiutiu, C. Hornung, C. Hassapoyannes, 2002, European journal of heart failure.

Effect of platelet inhibition with cangrelor during PCI on ischemic events.

Gregg W Stone, Matthew J Price, Deepak L. Bhatt, 2013, The New England journal of medicine.

Bleeding Risk Factors Affecting Warfarin Therapy in the Elderly With Atrial Fibrillation

J. A. Manfredi, Stephanie C. Davis, B. Mclaurin, 2014, Dimensions of critical care nursing : DCCN.

Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial

Deepak L. Bhatt, H. White, G. Stone, 2013, Coronary artery disease.

Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes.

G. Stone, M. York, A. Lincoff, 2008, Journal of the American College of Cardiology.

Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.

J. Ware, S. Pocock, H. White, 2007, JAMA.

Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial

J. Ware, S. Pocock, H. White, 2007, The Lancet.

Bivalirudin for patients with acute coronary syndromes.

Adelaide, J. Ware, S. Pocock, 2006, The New England journal of medicine.

One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients

M. Price, G. Stone, A. Kirtane, 2020, Circulation. Cardiovascular interventions.

Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)

P. Ponikowski, S. Solomon, M. Pfeffer, 2013, European journal of heart failure.

Outcomes of patients with prior coronary artery bypass grafting and acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.

G. Stone, R. Mehran, D. Cox, 2012, JACC. Cardiovascular interventions.

Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial

H. White, E. Ohman, G. Stone, 2011, Journal of Thrombosis and Thrombolysis.

Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.

B. Gersh, S. Pocock, H. White, 2009, Journal of the American College of Cardiology.

Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.

H. White, E. Ohman, G. Stone, 2009, Journal of the American College of Cardiology.

Are adverse events following an invasive strategy in patients with non‐ST‐segment elevation acute coronary syndromes more frequent at US sites versus Non‐US sites? analysis from the ACUITY trial

G. Stone, R. Mehran, M. Fahy, 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

A novel filter-based distal embolic protection device for percutaneous intervention of saphenous vein graft lesions: results of the AMEthyst randomized controlled trial.

J. Massaro, P. Zimetbaum, L. Mauri, 2008, JACC. Cardiovascular interventions.

First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter.

Shigeru Saito, Matthew J Price, Minglei Liu, 2017, JACC. Cardiovascular interventions.

The Supreme Biodegradable Polymer DES in Acute and Chronic Coronary Syndromes: A PIONEER III Substudy

S. Saito, A. Baumbach, M. Leon, 2023, Journal of the Society for Cardiovascular Angiography & Interventions.

A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial.

P. Fitzgerald, A. Kirtane, M. Leon, 2010, Journal of the American College of Cardiology.

Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.

P. Fitzgerald, A. Kirtane, M. Leon, 2009, JACC. Cardiovascular interventions.

Early Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Drug-Eluting and Bare Metal Stents: The Acute Catheterization and Urgent Intervention Triage Strategy Trial

H. White, E. Ohman, G. Stone, 2009, Circulation.

Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial

Manesh R. Patel, Neha J. Pagidipati, J. Stehli, 2020, The Lancet.

Abstract 4949: Bleeding and Ischemic Complications in Patients With Acute Coronary Syndromes and Chronic Kidney Disease in Relation to Different Glycoprotein IIb/IIIa Inhibitors: Analysis From the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) Trial

G. Stone, R. Mehran, A. Lansky, 2009 .

Impact of Femoral Vascular Closure Devices and Antithrombotic Therapy on Access Site Bleeding in Acute Coronary Syndromes: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Trial

G. Stone, R. Mehran, R. Ebrahimi, 2010, Circulation. Cardiovascular interventions.

Frequency and Clinical Consequences Associated With Sidebranch Occlusion During Stent Implantation Using Zotarolimus-Eluting and Paclitaxel-Eluting Coronary Stents

A. Kirtane, M. Leon, L. Mauri, 2009, Circulation. Cardiovascular interventions.

Implications of pre-procedural TIMI flow in patients with non ST-segment elevation acute coronary syndromes undergoing percutaneous coronary revascularization: insights from the ACUITY trial.

G. Stone, R. Mehran, G. De Luca, 2013, International journal of cardiology.

Geographic Variations on the Safety and Efficacy of the Supreme Biodegradable Polymer DES: Results From PIONEER III

A. Baumbach, S. Windecker, A. Lansky, 2022, Journal of the Society for Cardiovascular Angiography & Interventions.

A RANDOMIZED COMPARISON OF THE ENDEAVOR DRUG (ABT-578) ELUTING STENT VERSUS TAXUS PACLITAXEL-ELUTING STENT IN DIABETIC PATIENTS: THREE-YEAR OUTCOMES FROM ENDEAVOR IV

A. Kirtane, M. Leon, D. Kandzari, 2010 .

A prospective, randomized trial of bivaliruclin in acute coronary syndromes: One year results from the ACUITY Trial

J. Ware, S. Pocock, H. White, 2007 .

Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry

James S. Crenshaw, R. D. Jenkins, David W. Smith, 2023, EClinicalMedicine.

H. White, G. Stone, G. Dangas, 2009, Journal of the American College of Cardiology.

M. York, A. Lincoff, R. Mehran, 2008, Journal of the American College of Cardiology.

A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial.

P. Fitzgerald, A. Kirtane, M. Leon, 2010, Journal of the American College of Cardiology.

Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial

Pedro F. Campos, Luciano Lopes de Sousa, Howard D. Rubenstein, 2023, European heart journal.

Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications.

R. Wilensky, J. Stehli, K. Kario, 2023, Journal of the American College of Cardiology.